Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
To assess whether indoor residual spraying can provide additional protection against clinical malaria over current best practice of long-lasting insecticidal mosquito nets in The Gambia: study protocol for a two-armed cluster-randomised trial.
Pinder M, Jawara M, Jarju LB, Kandeh B, Jeffries D, Lluberas MF, Mueller J, Parker D, Bojang K, Conway DJ, Lindsay SW. Pinder M, et al. Among authors: jeffries d. Trials. 2011 Jun 10;12:147. doi: 10.1186/1745-6215-12-147. Trials. 2011. PMID: 21663656 Free PMC article. Clinical Trial.
The RooPfs study to assess whether improved housing provides additional protection against clinical malaria over current best practice in The Gambia: study protocol for a randomized controlled study and ancillary studies.
Pinder M, Conteh L, Jeffries D, Jones C, Knudsen J, Kandeh B, Jawara M, Sicuri E, D'Alessandro U, Lindsay SW. Pinder M, et al. Among authors: d alessandro u, jeffries d. Trials. 2016 Jun 3;17(1):275. doi: 10.1186/s13063-016-1400-7. Trials. 2016. PMID: 27255167 Free PMC article. Clinical Trial.
Improved housing versus usual practice for additional protection against clinical malaria in The Gambia (RooPfs): a household-randomised controlled trial.
Pinder M, Bradley J, Jawara M, Affara M, Conteh L, Correa S, Jeffries D, Jones C, Kandeh B, Knudsen J, Olatunji Y, Sicuri E, D'Alessandro U, Lindsay SW. Pinder M, et al. Among authors: d alessandro u, jeffries d. Lancet Planet Health. 2021 Apr;5(4):e220-e229. doi: 10.1016/S2542-5196(21)00002-4. Lancet Planet Health. 2021. PMID: 33838737 Free PMC article. Clinical Trial.
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].
Adigweme I, Akpalu E, Yisa M, Donkor S, Jarju LB, Danso B, Mendy A, Jeffries D, Njie A, Bruce A, Royals M, Goodson JL, Prausnitz MR, McAllister D, Rota PA, Henry S, Clarke E. Adigweme I, et al. Among authors: jeffries d. Trials. 2022 Sep 14;23(1):775. doi: 10.1186/s13063-022-06493-5. Trials. 2022. PMID: 36104719 Free PMC article.
351 results